FDA approves rapid-acting inhaled insulin for children
· Medical Xpressby Lori Solomon
edited by Gaby Clark, reviewed by Andrew Zinin
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Lead Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
reputable news agency
proofread
The GIST Add as preferred source
The U.S. Food and Drug Administration has approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6 years and older who are living with type 1 or type 2 diabetes.
Afrezza delivers insulin through the lungs using MannKind's proprietary Technosphere drug-delivery platform, which enables rapid absorption of insulin. Afrezza is taken when eating to closely mimic the body's natural insulin response at mealtime. Afrezza is already approved for use in adults.
The approval was based on results from the phase 3 INHALE-1 study of pediatric patients, along with clinical efficacy and safety evidence of Technosphere inhaled insulin use across more than 20 years and thousands of patients.
"For more than a century, insulin therapy for children living with diabetes has largely meant multiple daily injections," Michael Castagna, Pharm.D., the chief executive officer of MannKind, said in a statement. "Afrezza allows dosing at the moment of eating, without the need for premeal planning, making it a practical option for unplanned meals and snacks on the go."
Expanded approval of Afrezza was granted to MannKind.
More information
Key medical concepts
Clinical categories
EndocrinologyPediatrics Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 HealthDay. All rights reserved.
Citation: FDA approves rapid-acting inhaled insulin for children (2026, June 12) retrieved 12 June 2026 from https://medicalxpress.com/news/2026-06-fda-rapid-inhaled-insulin-children.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.